StrataGent Raises $16 Million

StrataGent Life Sciences Inc., a San Jose, Calif.-based developer of non-invasive versions of drugs that would otherwise be injected, has raised $16 million in Series B funding. Essex Woodlands Health Ventures led the deal, and was joined by Aphelion Capital and return backer Quantum Technology Partners.